Kornimate/medical-research-clean huggingface dataset:
compare the therapeutic effect treated with tamsulosin and progesterone after eswl( extra corporeal shock wave lithotripsy) in urinary calculus

Conditions: Urinary Calculus

Summary: the purpose of this study is to compare the stone clearance rate treated with different drugs after eswl in urinary calculus,these drugs are often used in urinary calculus,such as progesterone,tamsulosin,propantheline bromide and nifedipine.in these study the investigators want to investigate different effect of these drugs use to treat urinary calculus after eswl.

there is 4 groups in these investigation, group1 urinary calculus treated with eswl only ,group2 urinary calculus treated with eswl and tamsulosin,group3 urinary calculus treated with eswl and progesterone,group4 urinary calculus treated with eswl ,propantheline bromide and nifedipine.we want to investigate which one is better or not in urinary calculus treated with eswl .

Eligibility criteria:
inclusion criteria: * from 18 years old to 68 years old, * urinary calculus could be treated by eswl, * the calculus size is from 4-25mm exclusion criteria: * less than 18 years old or more than 68 years old, * the calculus size is from less than4 or larger than 25mm

Keywords: eswl urinary calculus drugs treat
endoscopic bariatric therapies (ebts): a retrospective and prospective multicenter registry

Conditions: Obesity; Weight Loss; Gastro Esophageal Reflux; Bariatric Surgery Candidate

Summary: the purpose of this registry study is to collect data through medical chart review and in patient visits on the efficacy and safety of various endoscopic bariatric therapies (ebts). this is a retrospective and prospective, observational, medical chart review study for at least 6 standard of care visits up to 1 years after a subject consents for study participation.

endoscopic bariatric therapies such as intragastric balloons, space occupying ebts, endoscopic sleeve gastroplasty (esg), primary obesity surgery endolumenal (pose), and small bowel interventions including gastrointestinal bypass sleeves, etc. are recommended alone or in conjunction with other weight loss treatment modules for patients who cannot or do not want to undergo conventional bariatric surgery or other therapies for obesity (with bmi ≥30 kg/m2) or bmi \>27 with comorbidities. this research is being done in order to find out if endoscopic bariatric therapies work as well as, or better or worse than, other currently available treatment modules to achieve weight loss. the study is to create a registry to analyze a longitudinal observational cohort of patients who have undergone endobariatric procedures. we will collect information through standard of practice visits and through chart review. laboratory data, patient characteristics, imaging, histology will be collected. in certain patients - after specific consent extra blood may be collected for research purposes.

Eligibility criteria:
inclusion criteria: * any patient who is considering undergoing ebt for weight loss within 6 months, or has undergone clinically indicated ebt for weight loss within the past 6 months * above or equal to 18 years of age. exclusion criteria: * any patient who has not undergone or will undergo ebt for weight loss * below 18 years of age.
reference values for compound muscle action potential amplitude obtained by direct muscle stimulation

Conditions: Critical Illness Polyneuromyopathy

Summary: direct muscle stimulation (dms) method is one of the electrodiagnostic methods used in the diagnosis of critical illness myopathy (cim) and critical illness neuropathy (cin). the ratio of amplitude of compound muscle action potential (cmap) obtained by nerve stimulation (ncmap) to amplitude of cmap obtained by dms (dmcmap) can be used to differentiate these two diseases. although not certain, if the ratio is \ 0.5 is considered to be a finding supporting cim. the investigators aimed to find the reference values of the ratio from healthy individuals. a monopolar needle electrode was used for dms. the dmcmap and ncmap were recorded with a concentric needle. the ratio was calculated by using amplitudes of dmcmap and ncmap obtained from deltoid and tibialis anterior muscles.

age, gender, height, weight, body mass index and neurological examination findings of the participants were recorded. healthy participants were not included if they had; polyneuropathy or a disease such as diabetes mellitus that causes polyneuropathy, complaints such as weakness or paresthesia, a neurodegenerative disease, abnormal neurological examination, myopathy or hereditary polyneuropathy in family history. in addition, healthy participants were excluded if the conventional nerve conduction study and needle electromyography (emg) findings were abnormal. median, ulnar, posterior tibial, peroneal, superficial peroneal, sural nerve conduction studies were performed to all participants. needle emg and direct muscle stimulation were applied to the deltoid and tibialis anterior muscles of the healthy participants.

Eligibility criteria:
inclusion criteria: * healthy individuals exclusion criteria: * polyneuropathy * a disease such as diabetes mellitus that causes polyneuropathy * complaints such as weakness or paresthesia * a neurodegenerative disease * abnormal neurological examination

Keywords: critical illness myopathy critical illness neuropathy direct muscle stimulation
the prediction and prevention of disease by using big data in motion analysis

Conditions: Ankylosing Spondylitis; Adolescent Idiopathic Scoliosis; Gait Analysis

Summary: variable patterns of gait disturbance can be found in patients with spine disease including the problems of gait initiation, freezing of gait, reduced balance and postural control, reduced step lengths, increased step times, and slow walking speed.


Eligibility criteria:
inclusion criteria: * pusan national university hospital orthopedics, otorhinolaryngology, neurology outpatient or inpatient who agreed to the study. * for adult men and women 18 years of age or older. exclusion criteria: * patients unable to walk independently.

Keywords: gait analysis spine
alleviating geriatric inpatients' medication-related iatrogenesis

Conditions: Iatrogenic Disease; Risk Reduction

Summary: this study will evaluate the medwise risk score™ (mwrs™), a holistic approach to quantifying the risk of a patient's medication regimen. high risk patients will be identified at hospital discharge. targeted interventions will be made to reduce their mwrs™ with a 30-day follow up. the hypothesis being tested is that a reduction in mwrs™ will lead to reduced 30-day readmission.


Eligibility criteria:
inclusion criteria: * hospital admission for at least 48 hours * prescribed at least 5 medications at hospital discharge * baseline medication risk score of 20 or more exclusion criteria: * reside greater than 25 miles from the index facility * discharge to hospice * discharge against medical advice * patient expiration during initial hospitalization
a phase i evaluation of the safety of the trivascular stent-graft system in the treatment of abdominal aortic aneurysms

Conditions: Abdominal Aortic Aneurysm

Summary: this study was a prospective observational study examined the safety of the trivascular aaa stent-graft system in the elective treatment of patients with abdominal aortic aneurysms. specifically, the study will evaluate the safety of the trivascualr aaa stent-graft system, evaluate the ability to deliver the tri-vascular aaa stent-graft system to the desired location within the aorta, and evaluate the ability of the trivascular aaa stent-graft to exclude the abdominal aortic aneurysm.


Eligibility criteria:
inclusion criteria: * male or infertile female * have signed an informed consent form. * are considered an appropriate candidate for open surgical repair of an abdominal aortic aneurysm. * at least one of the following: abdominal aortic aneurysm \>= 4.5 cm in diameter; aneurysm has increased in size by 0.5cm in last 6 months; maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent normal aortic segment; saccular aneurysm larger than 3 cm. * have patent iliac or femoral arteries that allow endovascular access to the aneurysmal site with a 17f delivery catheter. exclusion criteria: * a dissecting, acutely ruptured, or leaking aneurysm, or an acute vascular injury due to trauma. * a need for emergent surgery. * contraindication to undergoing angiography. * a thoracic aortic aneurysm that requires treatment. * presence of thrombus or atheroma in proximal aortic neck covering \> 50% of the endoluminal surface. * presence of diffuse atherosclerotic disease in either common iliac artery that reduces the iliac artery diameter to \<7mm. * congenital abnormalities in which the placement of the stent-graft will cause occlusion of major arterial flow. such abnormalities should be evaluated(e.g. angiography or ct) prior to treatment. * unstable angina * morbid obesity or other clinical conditions that severely inhibit x-ray visualization of the aorta. * connective tissue disease (e.g., marfan's or ehlers-danlos syndrome.) * hypercoagulable state. * contraindication for anticoagulation. * acute renal failure. * active systemic infection. * less than 18 years of age. * life expectancy less than 1 year. * current, or anticipated participation within 1 year, in another research study involving an investigational device or new drug (with the exception of participation in the lifeline registry of endovascular therapy). * other medical, social, or psychological issues that in the opinion of the investigator preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.

Keywords: abdominal aortic aneurysm aaa trivascular stent-graft system stent-graft
transperineal, mri-guided, prostate biopsy

Conditions: Prostate Cancer

Summary: primary purpose: complications and rehospitalizations after transperineal prostate biopsy mri-guided are reduced than transrectal prostate biopsies. secondary purposes: * patients tolerance after transperineal prostate biopsy mri-guided is better than after transrectal prostate biopsies. * core of transperineal prostate biopsies are better than core of transrectal prostate biopsies * study of correlation between radiologic images and anatomopathologic result * description of needle track during the procedure * description of real time template saturation prostate biopsy * comparison of transperineal prostate biopsy relevance according to ebm * comparison of 1.5t mri and 3t mri for prostate cancer detection


Eligibility criteria:
inclusion criteria: * men * 40 to 80 years' old * affiliation to french social health system * signed consent * prostate cancer suspicion based on prostate specific antigen (psa) or digital rectal exam with abnormal mri (prostate imaging reporting and data system score 3) and negative transrectal prostate biopsies * patient treated by active surveillance for a low risk prostate cancer (t1c or t2a, gleason = 6, psa \< 10) exclusion criteria: * gleason \> 6 prostate cancer * metastatic prostate cancer * contraindication to mri * contraindication to general anesthesia * non-reversible hemostasis trouble * inability to give consent
ldr vs. hdr brachytherapy for prostate cancer

Conditions: Prostate Cancer

Summary: h17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy as monotherapy. this is a continuation with expanded accrual of the randomized pilot study h15-02103

men suitable for prostate brachytherapy as monotherapy will undergo multiparametric magnetic resonance imaging for staging and identification of a dominant lesion and will be randomly selected for either a single low dose rate permanent seed implant or 2 fractions of high dose rate brachytherapy. using image registration techniques, dominant lesions will be biopsied under anesthesia at the start of the brachytherapy procedure. biopsies will reviewed for tumor gleason score and sent for cell cycle progression testing (prolaris). patients receiving high dose rate brachytherapy will also have biopsies between the 2 fractions to assess tumor changes induced from the first fraction. post implant quality assurance will determine the dose to the dominant lesions and compare these between the 2 types of brachytherapy. post implant symptoms will be tracked for severity and time course.

Eligibility criteria:
inclusion criteria: favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years. * clinical stage t1c-t2b, psa \< 20, gleason \< 8 * ecog 0-1 * low tier intermediate-risk prostate cancer is defined by a single nccn intermediate risk factor * extensive favorable-risk disease is defined as: * clinical stage t1c-t2a * psa \< 10 * gleason 6 * ≥ 50% of biopsy cores containing cancer * psa density \> 0.2 ng/cc * selected intermediate risk patients not defined above * - t1c/t2a * - psa \< 10 * -gleason 4+3 * -\< 33% of cores involved * -max tumor length in any core 10 mm * no androgen deprivation therapy (adt) * prostate volume by trus ≤ 60 cc. * not eligible for, or accepting of, active surveillance according to nccn guidelines. * signed study specific informed consent. exclusion criteria: * prior radical surgery for carcinoma of the prostate, * prior pelvic radiation * prior chemotherapy for prostate cancer, * prior turp or cryosurgery of the prostate * claustrophobic or unable to undergo mri

Keywords: brachytherapy quality of life high dose rate vs. low dose rate intermediate risk group
the effect of iyengar yoga practice on patients with multiple sclerosis

Conditions: Multiple Sclerosis, Iyenagar Yoga, Yoga, EDSS

Summary: the aim of this work is to find out what effect the practice of iyengar yoga has on patients with multiple sclerosis on the edss 5 and more, specifically in the field of mobility, self-sufficiency and anxiety.


Eligibility criteria:
inclusion criteria: * age over 18 years * diagnosis of multiple sclerosis * edss grade 5 or higher exclusion criteria: * age less than 18 years * the patient is not diagnosed with multiple sclerosis edss grade less than 5 * refusal of the subject to participate in the study
involvement of sk3 calcium channel in taxane neuropathy

Conditions: Breast Cancer; Chemotherapy-induced Peripheral Neuropathy; Prostate Cancer

Summary: taxane neuropathy is a common and long-term side effect of long-term morbidity in patients surviving cancer. no preventive or symptomatic treatment has been shown to be effective. its pathophysiology is poorly known and probably multifactorial. a possible mechanism would be mediated by the activation of the sk3 calcium channel: a retrospective study carried out at the university hospital of tours (carina rua) found a significant association between the number of cag triplets in the kcnn3 gene coding for the sk3 channel and the appearance of a taxane neuropathy.

patients hospitalized in medical oncology day hospital at the university hospital of tours or chc oncology day hospital, for their chemotherapy with taxanes (paclitaxel or docetaxel) for breast or prostate cancer, will be offered the study. the mode of administration of chemotherapy and the usual follow-up will not be modified by the protocol the determination of the sk3 status will be made from an additional tube collected during a collection as part of the treatment at the first arrival in a day hospital (no more blood tests). blood sample of 7ml. shipments and analyzes of samples in tours in the pharmacogenetics laboratory under the responsibility of dr. barin-le guellec. this study is non-invasive, without impact on the therapeutic management. the result of the polymorphism of sk3 will not be indicated in the record, so as not to influence the follow-up of the treatment and to allow an evaluation of the occurrence of peripheral neuropathy in blindness of the number of repetitions of the cag triplet of the kcnn3 gene.

Eligibility criteria:
inclusion criteria: breast group * age ≥ 18 years * breast cancer * chemotherapy with paclitaxel or docetaxel * adjuvant or neoadjuvant chemotherapy in localized cancer or first-line treatment in metastatic cancer * signed informed consent prostate group * age ≥ 18 years * metastatic prostate cancer * chemotherapy with docetaxel in 1st line * signed informed consent exclusion criteria: * anteriority or concomitance of another chemotherapy provider of neuropathy (platinum salts) * another possible cause of neuropathy: diabetes, alcoholism, vitamin b9 / b12 deficiency, neurodegenerative disease, raynaud's syndrome
evaluating the efficacy and safety of tjo-087 in moderate to severe dry eye disease patients

Conditions: Dry Eye Syndrome

Summary: the purpose of this clinical study is to prove that the test drug (tjo-087) is not clinically inferior to the control drug after 32 weeks of administration to patients with suppressed tear production due to moderate or severe dry eye syndrome.


Eligibility criteria:
inclusion criteria: * male or female, age 20 or over * patients with moderate to severe dry eye * screening both eyes, the corrected visual acuity is 0.2 or more * written informed consent to participate in the trial exclusion criteria: * screening visits within 2 weeks who treated with topical nsaids/hyaluronate sodium ophthalmic solutions * screening visits within 2 months the patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease) * intraocular pressure(iop)\> 25 mmhg * patient using or to use punctual plug within 1 months. * patients with contact lens.
telephone-based support for caregivers of patients with dementia

Conditions: Dementia

Summary: the purpose of this study is to develop an effective, low-cost, telephone-based intervention to reduce anxiety, depression, and feelings of burden and stress in caregivers of patients with dementia. this study will also determine whether the intervention can alter the course of dementia.

caregivers are randomized to receive either telephone-based intervention or standard medical care. both groups receive a resource packet containing information about caring for someone with dementia and a list of local resources. caregivers in the intervention group also receive a series of telephone calls over 12 months, during which education, emotional support, and training in problem-solving skills are provided by trained therapists. caregivers in the standard care group receive no additional psychosocial intervention. participants are assessed pre-treatment, mid-treatment (6 months), post-treatment, and at a 3-month follow-up.

Eligibility criteria:
patient inclusion criteria: * dsm-iv diagnosis of dementia (vascular, mixed, or associated with alzheimer's disease) * lives in the community, including senior/retirement centers, but excluding nursing homes and assisted living centers * 50 years old or older * resides in southeastern new england caregiver inclusion criteria: * living with a person with dementia * provides care for at least 6 months for at least 4 hours a day * english as primary language * telephone access * resides in southeastern new england patient exclusion criteria: * major acute medical condition affecting independent functioning caregiver exclusion criteria: * acute medical illness * cognitive impairment as defined by an mmse score \< 25
elimination of albumin-bound substances by mars and prometheus

Conditions: Liver Failure

Summary: this trial compares the efficacy of two artificial liver support systems, mars (molecular adsorbents recirculating system) and prometheus (fpsa, fractionated plasma separation and adsorption), in removing albumin-bound substances such as bilirubin, bile acids, and cytokines.


Eligibility criteria:
inclusion criteria: * consecutive patients with acute-on-chronic liver failure (severe deterioration of chronic liver disease) unresponsive to standard medical treatment for \>=48 hours exclusion criteria: * arterial hypotension * extrahepatic malignancy

Keywords: acute-on-chronic liver failure, mars, prometheus, bilirubin, bile acids, cytokines
international multicenter comparative randomized placebo-controlled clinical study of efficacy and safety of bcd-085 in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: bcd-085-5 is an international, multicenter, randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of bcd-085. bcd-085 is a monoclonal antibody to interleukin 17. during bcd-085-5 trial patients with active ankylosing spondylitis will receive 120 mg of bcd-085 subcutaneously every other week or placebo up to week 16. starting from week 16 all patients will receive bcd-085. efficacy, pk and safety parameters will be evaluated.


Eligibility criteria:
inclusion criteria: * active ankylosing spondylitis according to modified criteria of new york classification (1984), that was diagnosed at least 3 months prior to screening. * active disease according to basdai (score 4 or more) if nonsteroidal antiinflammatory drugs were used in the last 3 month prior to screening. * mean backache intensity equals 4 points or more. exclusion criteria: * total spinal ankylosis. * previous treatment with anti-interleukin 17 drugs or anti-interleukin 17 receptor drugs. * prior use of \>2 biologics to tumor necrosis factor alfa. * prior use of live or attenuated vaccines for up to 8 weeks before signing informed consent. * prior use of alkylating agents for up to 12 months prior to signing informed consent.

Keywords: ankylosing spondylitis interleukin 17 monoclonal antibody netakimab
effects of a vaginal contraceptive ring on vaginal microbiota and local immunity

Conditions: Bacterial Vaginosis

Summary: to assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) cvr use among women either with bv or at high risk for bv. the investigators will also recruit women who are hsv2-infected.


Eligibility criteria:
inclusion criteria: * ≥18-40 year old women * bv+ by amsel criteria and nugent score or history of bv in the prior 6 months * willing to use the nuvaring as directed * not intending or wishing to become pregnant over the course of the study * capable of providing written informed consent exclusion criteria: * current pregnancy * desire/intent to become pregnant over the course of the study * women who are less than 6 weeks postpartum * contraindications to hormonal contraceptive use per package insert, including history of deep vein thrombosis, smoking in women older than 35 years * current iud * unable to comprehend consent material because of language barrier or psychological difficulty

Keywords: hsv-2 contraceptive vaginal ring